atorvastatin/Ω-3 fatty acid (UI018) / Korea United Pharm - LARVOL DELTA

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers. (PubMed, Pharmaceuticals (Basel)) - "The GMRs (90% Cis) for the co-administration at steady state of atorvastatin, 2-OH-atorvastatin, DHA, and EPA were 1.150 (0.990-1.335), 1.301 (1.2707-1.1401), 0.320 (0.243-0.422), and 0.589 (0.487-0.712), respectively. The 90% CIs for most primary endpoints were outside the range of typical bioequivalence, indicating a pharmacokinetic interaction between atorvastatin and omega-3."

Journal • PK/PD data • Dyslipidemia • Metabolic Disorders

Study to Evaluate the Safety and PK of UI018 (clinicaltrials.gov) - P1; N=44; Active, not recruiting; Sponsor: Korea United Pharm. Inc.; Recruiting ➔ Active, not recruiting; Trial primary completion date: Sep 2022 ➔ Nov 2021

Clinical • Enrollment closed • Trial primary completion date